SOPH SOPHiA GENETICS SA
Price Chart
Executive Summary
SOPHiA GENETICS announced a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) to form a joint venture aimed at creating a precision medicine hub for next-generation precision oncology. The JV would combine MSK's clinical data and expertise with SOPHiA's AI platform (SOPHiA DDM) to develop and deploy new diagnostic and therapeutic capabilities globally. The specifics of the initiative have yet to be finalized, and no financial terms were disclosed.
Actionable Insight
The MSK JV is a significant strategic validation for SOPHiA's AI platform and could drive long-term revenue growth through expanded diagnostics deployment and biopharma partnerships. However, the MOU is non-binding and specifics are TBD — monitor for definitive agreements and financial terms in coming quarters. The stock may see a positive reaction on the partnership's prestige, but near-term financial impact is uncertain.
Key Facts
- SOPHiA GENETICS signed an MOU with Memorial Sloan Kettering Cancer Center to form a joint venture for a precision medicine hub.
- The hub would combine MSK's clinical data and expertise with SOPHiA's AI platform (SOPHiA DDM) to develop next-generation precision oncology tools.
- SOPHiA DDM has analyzed over 2.5 million cases since 2014; MSK has sequenced over 150,000 tumor samples since 2014.
- Specifics of the initiative have yet to be finalized; no financial terms or timeline were disclosed.
- The MOU builds on prior successful license agreements between the two institutions for MSK-IMPACT and MSK-ACCESS assays.
Financial Impact
No financial terms disclosed; potential long-term revenue opportunity from expanded platform adoption and biopharma partnerships.
Risk Factors
- JV specifics are not finalized; the MOU is non-binding and may not lead to a definitive agreement.
- No financial terms disclosed — potential dilution or capital requirements for the JV are unknown.
- Execution risk in integrating MSK's data and clinical workflows with SOPHiA's platform.
- Regulatory and commercialization risks for new diagnostic products developed through the hub.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-040630 |
| Document: sophiamsk-pressreleasevf.htm | 0001628280-26-040630 |
| Document: 0001628280-26-040630-index-headers.html | 0001628280-26-040630 |
| Document: 0001628280-26-040630-index.html | 0001628280-26-040630 |
| Document: 0001628280-26-040630.txt | 0001628280-26-040630 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
6-K
| $4.96 $5.00 | ▲ +0.81% | ▲ +3.40% | $4.88 (−1.61%) |
|
Jun 1, 2026
13d ago
|
Insider Cluster
| $4.99 $4.94 | ▼ −1.00% | ▼ −1.15% | $4.88 (−2.20%) |
|
May 20, 2026
25d ago
|
Insider Cluster
| $5.05 $4.88 | ▼ −3.37% | ▼ −3.81% | $4.88 (−3.37%) |
|
May 19, 2026
26d ago
|
6-K
| $4.68 $4.87 | ▲ +4.06% | ▲ +3.02% | $4.88 (+4.27%) |
|
May 8, 2026
5w ago
|
6-K
| $5.15 $4.79 | ▼ −6.99% | ▼ −7.22% | $4.88 (−5.24%) |
|
May 5, 2026
5w ago
|
6-K
| $5.07 $5.02 | ▼ −0.99% | ▼ −2.37% | $4.88 (−3.75%) |
|
Apr 14, 2026
8w ago
|
Insider Cluster
| $4.96 $5.07 | ▼ −2.22% | ▼ −1.44% | $4.88 (+1.61%) |
|
Apr 8, 2026
9w ago
|
144
| $4.73 $4.70 | ▼ −0.63% | ▼ −0.57% | $4.88 (+3.17%) |
|
Apr 7, 2026
9w ago
|
Insider Cluster
| $4.90 $4.86 | ▼ −0.82% | ▼ −3.36% | $4.88 (−0.41%) |
|
Apr 6, 2026
10w ago
|
Insider Cluster
| $4.95 $4.90 | ▲ +1.01% | ▲ +1.07% | $4.88 (+1.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access